Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022023545 - PHARMACEUTICAL COMBINATION COMPRISING GLYCOLIC ACID AND L-ALANINE OR PYRUVATE

Publication Number WO/2022/023545
Publication Date 03.02.2022
International Application No. PCT/EP2021/071431
International Filing Date 30.07.2021
IPC
A61K 31/19 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
A61K 31/198 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
197the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
198Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
A61P 25/28 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 9/10 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
10for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 15/08 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15Drugs for genital or sexual disorders; Contraceptives
08for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
A61P 37/04 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
04Immunostimulants
CPC
A61K 31/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
A61K 31/198
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
197the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA],
A61P 15/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15Drugs for genital or sexual disorders
08for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
A61P 25/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 37/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
04Immunostimulants
A61P 9/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
10for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applicants
  • PAN-MONTOJO, Francisco [ES]/[DE]
Inventors
  • PAN-MONTOJO, Francisco
Agents
  • HERTIN UND PARTNER RECHTS- UND PATENTANWÄLTE
Priority Data
20188919.331.07.2020EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) PHARMACEUTICAL COMBINATION COMPRISING GLYCOLIC ACID AND L-ALANINE OR PYRUVATE
(FR) COMBINAISON PHARMACEUTIQUE COMPRENANT DE L'ACIDE GLYCOLIQUE ET DE LA L-ALANINE
Abstract
(EN) The invention relates to a pharmaceutical combination, comprising glycolic acid or a pharmaceutically acceptable salt or ester thereof, and L-alanine and/or pyruvate, or a pharmaceutically acceptable salt thereof. The combination of the invention optionally comprises D-lactate and/or phenylbutyrate and/or tauroursodeoxycholic acid, or pharmaceutically acceptable salts or esters thereof. Further aspects of the invention relate to the combination of the invention for use in the treatment of neurological medical conditions, for stimulating neuronal plasticity, for regulating intracellular calcium and/or for stimulating mitochondrial function and ATP production, thereby enabling a slowing, reversing and/or inhibiting of the ageing process and/or regulating, preferably stimulating, the immune system.
(FR) L'invention concerne une combinaison pharmaceutique, comprenant de l'acide glycolique ou un sel ou ester pharmaceutiquement acceptable associé, et de la L-alanine et/ou du pyruvate, ou un sel pharmaceutiquement acceptable associé. La combinaison de l'invention comprend éventuellement du D-lactate et/ou du phénylbutyrate et/ou de l'acide tauroursodésoxycholique, ou des sels ou esters pharmaceutiquement acceptables associés. D'autres aspects de l'invention concernent la combinaison de l'invention destinée à être utilisée dans le traitement d'états médicaux neurologiques, pour stimuler la plasticité neuronale, pour réguler le calcium intracellulaire et/ou pour stimuler la fonction mitochondriale et la production d'ATP, permettant ainsi un ralentissement, une inversion et/ou une inhibition du processus de vieillissement et/ou la régulation, de préférence la stimulation, du système immunitaire.
Latest bibliographic data on file with the International Bureau